TWIST BIOSCIENCE

The path to a DNA data storage product

Esther Singer
Director of Product and Market Development
Data Storage



APRIL 2024

Legal disclaimer

This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to statements regarding anticipated growth in demand for data storage; timing of the early access launch of Twist Bioscience's first DNA data storage solution; and the ability of Twist Bioscience's DNA data storage solution to enable cost-effective, scalable and sustainable archive storage. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties relating to COVID-19; the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies, including Abveris, and to achieve expected benefits from acquisitions; supply chain and other disruptions caused by the COVID-19 pandemic or otherwise; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience's patents or proprietary rights; and the risk that Twist Bioscience's proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience's business in general, see Twist Bioscience's risk factors set forth in Twist Bioscience's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 7, 2023 and subsequent filings with the SEC. Any forward-looking statements contained in this presentation speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Silicon-based DNA synthesis

Founded in 2013 to make synthetic DNA to improve health & sustainability

NASDAQ: TWST

FY23 Revenue $245M

Advanced DNA synthesis platform

Inkjet-based DNA synthesis

Products for Synthetic Biology, NGS, & Biopharma

Pioneers in DNA Data Storage

CMOS-based DNA synthesis

Developing Data Storage solutions

Value proposition for DNA data storage

- Data resilience
- Data sovereignty
- Data redundancy
- Sustainability

Challenges to rolling out a new data storage product

- Develop product specification
- Iterate with early adopter
- Achieve pilot production

Workflow update

Code

Codec delivers bit error rate comparable to HDD

Synthesis

Chips deliver TB-scale DNA – optimizing for throughput and cost

Storage

Installing Imagene large-capacity packaging system - working on fixity check

Sequencing

Electronic sequencing error rates are good enough to scale to required capacity



Decode

Codec delivers bit error rate comparable to HDD

Product evolution

Near Term: Service (Data in, DNA out)

- Hermetically packaged DNA
- Script for decoding sequencing data



Long Term: On-premise system

- Modular components
- SW stack

Conclusions

- Committed to delivering a TB-scale DNA data storage solution
- Ongoing product development, developing customer acceptance plan